Intensive research over the last 3 decades has unequivocally demonstrated the relevance of inflammation in heart failure (HF). Despite our current and ever increasing knowledge about inflammation, the clinical success of antiinflammatory and immunomodulatory therapies in HF is still limited. This review outlines the complexity and diversity of inflammation, its reciprocal interaction with HF, and addresses future perspectives, calling for immunomodulatory therapies that are specific for factors that activate the immune system without the risk of nonspecific immune suppression
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients w...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...
Despite mounting evidence demonstrating the significance of inflammation in the pathophysiological m...
Inflammation has emerged as an important contributor to heart failure (HF) development and progressi...
Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of...
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwi...
Inflammation has long been known to play a role in heart failure (HF). Earlier studies demonstrated ...
Heart failure (HF) is one of the most common cardiovascular diseases, affecting approximately 26 mil...
Myocarditis is a multifactorial disorder, characterized by an inflammatory reaction in the myocardiu...
It was established that in patients with chronic heart failure (CHF), including CHF with reduced eje...
The prevalence of chronic heart failure is still increasing making it a major health issue in the 21...
PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms...
Despite current treatment options, the clinical course of patients with chronic heart failure is not...
Aims The exploration of novel immunomodulatory interventions to improve outcome in heart failure (HF...
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients w...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...
Despite mounting evidence demonstrating the significance of inflammation in the pathophysiological m...
Inflammation has emerged as an important contributor to heart failure (HF) development and progressi...
Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of...
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwi...
Inflammation has long been known to play a role in heart failure (HF). Earlier studies demonstrated ...
Heart failure (HF) is one of the most common cardiovascular diseases, affecting approximately 26 mil...
Myocarditis is a multifactorial disorder, characterized by an inflammatory reaction in the myocardiu...
It was established that in patients with chronic heart failure (CHF), including CHF with reduced eje...
The prevalence of chronic heart failure is still increasing making it a major health issue in the 21...
PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms...
Despite current treatment options, the clinical course of patients with chronic heart failure is not...
Aims The exploration of novel immunomodulatory interventions to improve outcome in heart failure (HF...
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients w...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...
Cardiovascular disease is a leading cause of morbidity and mortality in the Western world and repres...